News | Contrast Media | March 24, 2021

Gadopiclenol is a high-relaxivity macrocyclic contrast agent used for magnetic resonance imaging (MRI)

Gadopiclenol is a high-relaxivity macrocyclic contrast agent used for magnetic resonance imaging (MRI)

March 24, 2021 — Guerbet announced positive results from two Phase III clinical studies comparing the diagnostic efficacy and safety of Gadopiclenol to Gadobutrol in a wide range of indications, covering the central nervous system and various other anatomical areas (head and neck, thorax, abdomen, pelvis, musculoskeletal system).

A total of 560 patients were recruited for these two studies in over 60 hospital medical imaging departments in 13 countries.

The endpoints were met in terms of the diagnostic benefit of injecting Gadopiclenol (0.05 mmol/kg) during MRI examinations, based on: 1/ the superiority of the examination with Gadopiclenol compared to the examination with no contrast agent; and 2/ the non-inferiority of Gadopiclenol (0.05 mmol/kg) compared to Gadobutrol (0.1 mmol/kg) for the visualization and detection of lesions of the central nervous system and in the other anatomical areas studied.

In addition to these Phase III trials, a study was conducted on 80 children between 2 and 17 years of age in 19 centers in five European countries. This study showed that the pharmacokinetic profile of Gadopiclenol at 0.05 mmol/kg in children was similar to that of adults. It will therefore be possible to extrapolate the efficacy of Gadopiclenol to the pediatric population based on data collected in adult patients.

No major safety signals were reported during the development of Gadopiclenol, and the adverse reactions reported during the two Phase III studies were similar for both of the products administered.

"We are very happy with the results of these studies, which demonstrate the diagnostic value and good tolerance of Gadopiclenol during an MRI examination in adults and children. By using a lower dose of gadolinium in clinical practice, we hope this macrocyclic contrast agent will become a 'best-in-class' diagnostic solution for doctors and their patients." said David Hale, CEO of Guerbet. 

All this data will serve as a basis for regulatory submissions, which will begin in the United States and in the European Union (EU) early 2022.

For more information: www.guerbet.com

 


Related Content

News | Digital Pathology

January 27, 2023 — Fujifilm has completed its asset purchase of Inspirata, Inc.’s digital pathology business effective ...

Time January 27, 2023
arrow
News | Magnetic Resonance Imaging (MRI)

January 25, 2023 — On November 11th, 2022 at the Southern Hills Hospital in Las Vegas, USA, Robotic Spine Surgeon Dr ...

Time January 25, 2023
arrow
Feature | Enterprise Imaging

The Imaging Technology News (ITN) team was saddened to hear of the untimely passing of Frank Pecaitis, US North American ...

Time January 24, 2023
arrow
Feature | Radiology Imaging | By Melinda Taschetta-Millane

Have you read the January/February 2023 issue of Imaging Technology News? If not, take some time out of your busy ...

Time January 24, 2023
arrow
News | Digital Radiography (DR)

January 24, 2023 — Carestream Health was awarded 20 new patents in 2022 for global advances in artificial intelligence ...

Time January 24, 2023
arrow
News | Radiology Imaging

January 23, 2023 — Canon Medical Systems has released a new eBook featuring its new medical imaging roadshow. This new ...

Time January 23, 2023
arrow
News | Ultrasound Imaging

January 23, 2023 — Clarius Mobile Health, a leading provider of high-definition handheld ultrasound systems, introduces ...

Time January 23, 2023
arrow
News | Artificial Intelligence

January 20, 2023 — Artificial intelligence (AI) can reconstruct coarsely-sampled, rapid magnetic resonance imaging (MRI) ...

Time January 20, 2023
arrow
News | Ultrasound Imaging

January 19, 2023 — Clarius Mobile Health, a leading provider of high-definition handheld ultrasound systems, introduces ...

Time January 19, 2023
arrow
Feature | Contrast Media Injectors | By Christine Book

The vital, and growing role of contrast media, and the medical devices employed to inject the agent into the body ...

Time January 19, 2023
arrow
Subscribe Now